BioPharma Earnings Roundup: AstraZeneca, Alnylam and Regeneron Results

AstraZeneca Cuts Costs for AI Pipeline While Regeneron Defeats Eylea Biosimilar Threat

Key Clinical Takeaways:

• AstraZeneca unveiled a $1.5 billion annual cost-savings program named “Reshaping for Sustainable Growth” to fund its drug pipeline using artificial intelligence, driving a 7% share increase on Friday.
• Alnylam Pharmaceuticals saw its stock drop over 20% following third-quarter earnings after insurers and proposed Medicare policy shifts dampened the sales trajectory for its heart disease drug Amvuttra.
• Regeneron Pharmaceuticals shares rose 13% after reporting net sales of $6.5 billion for Dupixent alongside strong performance from high-dose Eylea and Libtayo.

BioPharma Dive reported that three major pharmaceutical companies experienced starkly divergent investor reactions to their quarterly earnings updates. While AstraZeneca secured share price gains following its latest earnings report and cost-savings program, Alnylam surrendered its prior valuation gains amid mounting reimbursement headwinds.

AstraZeneca Targets $80 Billion Goal Through Artificial Intelligence Restructuring

AstraZeneca reaffirmed its commitment to reaching $80 billion in full-year revenue by 2030, despite encountering multiple clinical setbacks. CEO Pascal Soriot told analysts that the company has reported positive results from 12 late-stage programs and brought four new drugs to market since February. Over the next year, 20 high-value trial readouts could yield peak annual revenue opportunities surpassing $20 billion, according to Soriot.

Alongside its June-to-September financial results, the company introduced “Reshaping for Sustainable Growth,” a cost-savings program designed to trim $1.5 billion annually and reinvest those funds directly into drug research. Soriot stated that AstraZeneca has worked on the plan since the beginning of the year to redeploy resources toward its pipeline by embedding artificial intelligence more deeply into operations. AI is helping make operations faster and smarter, allowing the company to grow without adding as many personnel as traditional models require, Soriot noted. Finance chief Aradhana Sarin reported on a separate media call that the initiative is not expected to cause a net reduction in the size of the workforce. The company projects a one-time $2 billion restructuring charge tied to the program, and AstraZeneca shares climbed 7% on Friday.

Alnylam Gives Up Prior Gains Amid Amvuttra Commercial Headwinds

Alnylam Pharmaceuticals watched its share price tumble more than 20% as investors digested its latest financial disclosure. Two years prior, shares rocketed from around $160 in June 2024 to record highs above $480 after Amvuttra succeeded in a trial that determined its effectiveness for transthyretin amyloidosis cardiomyopathy. With the release of its third-quarter earnings, Alnylam has given all of that value back.

Although Alnylam reported $1.13 billion in third-quarter Amvuttra revenue that met Wall Street expectations, analysts grew skeptical of its future sales trajectory. William Blair analyst Myles Minter attributed the market cynicism to a proposed rule change that would substantially cut Medicare reimbursement for medicines acquired through the 340B drug discount program, alongside a restrictive first-line use policy adopted by UnitedHealth for certain patients. Stifel analyst Paul Matteis wrote that the near-term numbers for the drug are likely to decrease significantly, making it difficult to maintain a growth trajectory.

Regeneron Defeats Biosimilar Pressure With Dupixent and Eylea Sales

Regeneron Pharmaceuticals countered earlier market skepticism regarding biosimilar competition to its Eylea eye drug franchise by posting figures across its key product lines. Global net sales of Dupixent spiked 35% to $6.5 billion between June and September, with Regeneron capturing a larger share of the cash after settling research payments owed to partner Sanofi.

Among pipeline assets, Regeneron is advancing ALN-CIDEB, an RNA-based liver disease treatment licensed from Alnylam, with Phase 3 testing slated to begin by the end of the year following early data presentations.

Disclaimer: The information provided in this article is for educational and scientific communication purposes only and does not constitute medical advice. Always consult with a qualified healthcare provider regarding any medical condition, diagnosis, or treatment plan.